Combination therapy with transarterial chemoembolization and interferon-α compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma-Reference-Cited by-同舟云学术

Combination therapy with transarterial chemoembolization and interferon-α compared with transarterial chemoembolization alone for hepatitis B virus related unresectable hepatocellular carcinoma

Published:2009-08 Issue:8 Volume:24 Page:1437-1444
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:

Author:

Li Maoquan,Lu Chenhui,Cheng Jie,Zhang Jiaxing,Cao Chuanwu,Xu Jiahua,Xu Jichong,Pan Hui,Zhong Baoliang,Tucker Steven,Wang Daoyuan

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1440-1746.2009.05863.x/fullpdf

Reference40 articles.

1. Primary prevention of hepatocellular carcinoma;Yu;J. Gastroenterol. Hepatol.,1995

2. Hepatocellular carcinoma surveillance: who is the target population?;Bruix;Hepatology,2003

3. Prognostic prediction and treatment strategy in hepatocellular carcinoma;Bruix;Hepatology,2002

4. Hepatocellular carcinoma;Llovet;Lancet,2003

5. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival;Llovet;Hepatology,2003

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis;Hepatology International;2024-01-02

2. Interferon-α Research Progress in Prevention and Treatment of Hepatitis B Related Liver Cancer;Advances in Clinical Medicine;2023

3. Hepatitis B Before and After Hepatocellular Carcinoma;Journal of Gastrointestinal Cancer;2021-11-11

4. Enhanced delivery efficiency and sustained release of biopharmaceuticals by complexation-based gel encapsulated coated microneedles: rhIFNα-1b example;Asian Journal of Pharmaceutical Sciences;2021-09

5. Long-term clinical benefit of Peg-IFNα and NAs sequential anti-viral therapy on HBV related HCC;Neoplasma;2021